找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Clinical Pharmacology: Current Topics and Case Studies; Markus Müller (Professor and Head of Department) Book 20101st edition Springer-Ver

[復(fù)制鏈接]
樓主: monster
11#
發(fā)表于 2025-3-23 12:57:21 | 只看該作者
12#
發(fā)表于 2025-3-23 15:45:35 | 只看該作者
Current concepts of pharmacogenetics, pharmacogenomics, and the “druggable” genomelity can be translated into clinical practice. According to the current intriguing concepts of pharmacogenetics and pharmacogenomics, genetic information of individuals will be used to avoid “trial and error” scenarios during medication. Based on evidence from genomic testing, medicine is expected t
13#
發(fā)表于 2025-3-23 20:56:23 | 只看該作者
Biomarkerstifying biological markers as indicators for an underlying disease is an elementary concept in medicine. Since the beginning of the medical skill of healing, signs and symptoms have been interpreted by medical doctors and guided diagnosis and treatment of their patients. With the emergence of the bi
14#
發(fā)表于 2025-3-24 01:00:03 | 只看該作者
15#
發(fā)表于 2025-3-24 06:24:44 | 只看該作者
16#
發(fā)表于 2025-3-24 06:36:49 | 只看該作者
17#
發(fā)表于 2025-3-24 14:22:58 | 只看該作者
Safe Filler Injection Techniquesronic diseases and the determination of number of patients affected by a disease, the latter being a cornerstone of public healthcare and preventive medicine. Epidemiological research provides a methodological basis for determination of factors involved in disease progression and risk.
18#
發(fā)表于 2025-3-24 17:56:37 | 只看該作者
Epidemiology and bio statisticsronic diseases and the determination of number of patients affected by a disease, the latter being a cornerstone of public healthcare and preventive medicine. Epidemiological research provides a methodological basis for determination of factors involved in disease progression and risk.
19#
發(fā)表于 2025-3-24 22:53:03 | 只看該作者
Andrew M. Dearden,Michael D. Harrison, (b) clinically, by administering appropriate drug therapy to patients and (c) within a regulatory framework, to provide guidance on the risk/benefit ratio of drug candidates in drug development and drug reimbursement.
20#
發(fā)表于 2025-3-25 00:38:37 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-11 04:27
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
丰镇市| 襄垣县| 贵溪市| 天镇县| 兴安盟| 息烽县| 皋兰县| 黎川县| 印江| 昌黎县| 张家界市| 桦甸市| 沐川县| 柳林县| 武夷山市| 博乐市| 固镇县| 名山县| 德令哈市| 泌阳县| 修文县| 开江县| 阳东县| 黄龙县| 夏津县| 崇义县| 华亭县| 新巴尔虎左旗| 宿松县| 东乌珠穆沁旗| 海伦市| 通榆县| 吴桥县| 渭南市| 南宁市| 张家口市| 永平县| 饶河县| 炉霍县| 兰溪市| 麻江县|